Royce & Associates LP Trimmed Holding in Paratek Pharmaceuticals Inc (PRTK)

Royce & Associates LP Trimmed Holding in Paratek Pharmaceuticals Inc (PRTK)

Several other institutional investors also recently added to or reduced their stakes in PRTK. BlackRock Inc. increased its stake in Paratek Pharmaceuticals by 3.6% during the 3rd quarter. BlackRock Inc. now owns 2,677,154 shares of the specialty pharmaceutical company’s stock valued at $25,967,000 after purchasing an additional 93,764 shares in the last quarter. Highland Capital Management LP increased its stake in Paratek Pharmaceuticals by 38.4% during the 3rd quarter. Highland Capital Management LP now owns 2,654,428 shares of the specialty pharmaceutical company’s stock valued at $25,748,000 after purchasing an additional 736,550 shares in the last quarter. Vanguard Group Inc. increased its stake in Paratek Pharmaceuticals by 3.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,392,044 shares of the specialty pharmaceutical company’s stock valued at $13,504,000 after purchasing an additional 43,816 shares in the last quarter. Vanguard Group Inc increased its stake in Paratek Pharmaceuticals by 3.2% during the 3rd quarter. Vanguard Group Inc now owns 1,392,044 shares of the specialty pharmaceutical company’s stock valued at $13,504,000 after purchasing an additional 43,816 shares in the last quarter. Finally, Water Island Capital LLC increased its stake in Paratek Pharmaceuticals by 53.5% during the 3rd quarter. Water Island Capital LLC now owns 439,726 shares of the specialty pharmaceutical company’s stock valued at $4,265,000 after purchasing an additional 153,226 shares in the last quarter. Institutional investors own 73.44% of the company’s stock.

Royce & Associates LP lessened its stake in shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 19.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 317,700 shares of the specialty pharmaceutical company’s stock after selling 76,669 shares during the period. Royce & Associates LP owned 0.99% of Paratek Pharmaceuticals worth $1,630,000 at the end of the most recent reporting period.

In other news, Director Thomas John Dietz sold 9,330 shares of the company’s stock in a transaction on Friday, December 21st. The shares were sold at an average price of $5.01, for a total value of $46,743.30. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at approximately $37,575. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 16,531 shares of company stock valued at $96,743. Company insiders own 6.20% of the company’s stock.

NASDAQ PRTK opened at $6.46 on Thursday. Paratek Pharmaceuticals Inc has a 1 year low of $4.50 and a 1 year high of $14.90. The company has a debt-to-equity ratio of 4.81, a current ratio of 14.41 and a quick ratio of 14.41. The firm has a market capitalization of $204.87 million, a PE ratio of -1.81 and a beta of 1.55.

A number of analysts have commented on PRTK shares. Canaccord Genuity boosted their price target on shares of Paratek Pharmaceuticals from $14.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, January 16th. HC Wainwright decreased their price target on shares of Paratek Pharmaceuticals from $55.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, November 23rd. LADENBURG THALM/SH SH restated a “buy” rating and set a $18.00 price target on shares of Paratek Pharmaceuticals in a research note on Tuesday, December 18th. ValuEngine lowered shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. Finally, Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 15th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $23.25.

Paratek Pharmaceuticals Profile

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Further Reading: What is a Reverse Stock Split?

Related posts

Leave a Comment